Not Signed In -
Xifaxan |
Rifaximin |
Article: Rifaximin
| Image:Rifaximin.png | |
| Rifaximin | |
| Systematic (IUPAC) name | |
| (2S,16Z,18E,20S,21S,22R,23R,24R,25S,26S,27S,28E)-5,6,21,23,25-pentahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-2,7-(epoxypentadeca-[1,11,13]trienimino)benzofuro[4,5-e]pyrido[1,2-a]-benzimida-zole-1,15(2H)-dione,25-acetate | |
| Identifiers | |
| CAS number | 80621-81-4 |
| ATC code | A07AA11 D06AX11 |
| PubChem | 6436173 |
| DrugBank | APRD01218 |
| Chemical data | |
| Formula | C43H51N3O11 |
| Mol. weight | 785.879 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. | C |
| Legal status | Rx Only |
| Routes | ? |
Rifaximin Xifaxan
Rifaximin is a semisynthetic, rifamycin-based non-systematic antibiotic, meaning that the drug will not pass the gastrointestinal wall into the circulation as is common for other types of orally administered antibiotics. It is primarily used to treat diarrhea caused by E. coli, but recent studies published in the American Journal of Gastroenterology suggest its efficacy in relieving chronic functional symptoms of bloating and flatulence that are common in gastrointestinal disorders, such as Irritable Bowel Syndrome.
It is currently sold under the brand name Xifaxan® by Salix Pharmaceuticals.
Resources
- Xifaxan Consumer Information (U.S. Food and Drug Administration)
email this page
print this page
bookmark this page
feedback on this page
